S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NYSE:MYOV

Myovant Sciences - MYOV Stock Forecast, Price & News

$17.51
-0.72 (-3.95%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.40
▼
$18.01
50-Day Range
$10.38
▼
$18.49
52-Week Range
$7.67
▼
$27.43
Volume
513,597 shs
Average Volume
793,201 shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Myovant Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
0.9% Upside
$17.67 Price Target
Short Interest
Healthy
6.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Myovant Sciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$702,389 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.82) to ($1.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

1091st out of 1,116 stocks

Pharmaceutical Preparations Industry

530th out of 545 stocks

See Top Rated MarketRank™ Stocks Here
MYOV stock logo

About Myovant Sciences (NYSE:MYOV) Stock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Myovant Sciences from $9.00 to $10.00 and gave the company a "neutral" rating in a research report on Thursday, July 28th. SVB Leerink upgraded shares of Myovant Sciences from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $12.00 to $23.00 in a research report on Tuesday, August 9th.

Myovant Sciences Price Performance

MYOV Stock opened at $18.23 on Friday. The company has a 50 day simple moving average of $13.54 and a 200 day simple moving average of $12.43. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -10.36 and a beta of 2.40. Myovant Sciences has a 1 year low of $7.67 and a 1 year high of $27.43.

Insiders Place Their Bets

In other Myovant Sciences news, General Counsel Matthew Lang sold 31,214 shares of the business's stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $18.23, for a total transaction of $569,031.22. Following the sale, the general counsel now directly owns 363,966 shares of the company's stock, valued at approximately $6,635,100.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Myovant Sciences news, General Counsel Matthew Lang sold 31,214 shares of the business's stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $18.23, for a total transaction of $569,031.22. Following the sale, the general counsel now directly owns 363,966 shares of the company's stock, valued at approximately $6,635,100.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ferreira Juan Camilo Arjona sold 2,755 shares of the business's stock in a transaction that occurred on Wednesday, July 6th. The stock was sold at an average price of $13.40, for a total transaction of $36,917.00. Following the sale, the insider now directly owns 255,992 shares in the company, valued at $3,430,292.80. The disclosure for this sale can be found here. Insiders have sold 41,310 shares of company stock valued at $702,389 in the last ninety days. 1.90% of the stock is currently owned by insiders.

Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Stock News Headlines

August 19, 2022 | americanbankingnews.com
Myovant Sciences Ltd. (NYSE:MYOV) General Counsel Sells $569,031.22 in Stock
August 14, 2022 | seekingalpha.com
Biotech Analysis Central Preview Series: Myovant Sciences
August 13, 2022 | nasdaq.com
Myovant Sciences Ltd Shares Close the Week 20.8% Higher - Weekly Wrap
August 13, 2022 | americanbankingnews.com
Myovant Sciences Ltd. (NYSE:MYOV) to Post Q2 2023 Earnings of ($0.48) Per Share, SVB Leerink Forecasts
August 12, 2022 | nasdaq.com
Myovant Sciences (NYSE:MYOV) delivers shareholders strong 32% CAGR over 3 years, surging 21% in the last week alone
August 11, 2022 | seekingalpha.com
Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
August 11, 2022 | americanbankingnews.com
Myovant Sciences (NYSE:MYOV) Stock Rating Upgraded by SVB Leerink
August 10, 2022 | americanbankingnews.com
Myovant Sciences (NYSE:MYOV) Shares Gap Up to $15.12
August 8, 2022 | msn.com
USFDA approves Myovant & Pfizer’s Myfembree for management of moderate to severe pain associated with endometriosis
August 8, 2022 | marketwatch.com
Myovant Shares Jump Premarket on FDA Expanded OK of Myfembree
August 6, 2022 | finance.yahoo.com
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
August 2, 2022 | americanbankingnews.com
SVB Leerink Weighs in on Myovant Sciences Ltd.'s Q2 2023 Earnings (NYSE:MYOV)
July 30, 2022 | finance.yahoo.com
What You Need To Know About Myovant Sciences Ltd.'s (NYSE:MYOV) Investor Composition
July 29, 2022 | americanbankingnews.com
The Goldman Sachs Group Increases Myovant Sciences (NYSE:MYOV) Price Target to $10.00
July 28, 2022 | markets.businessinsider.com
Here's what to expect from Myovant Sciences's earnings report
July 27, 2022 | seekingalpha.com
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2022 Results - Earnings Call Transcript
July 27, 2022 | finance.yahoo.com
Myovant Sciences (MYOV) Reports Q1 Loss, Tops Revenue Estimates
July 27, 2022 | finance.yahoo.com
Myovant Sciences Ltd. (MYOV) Q1 2022 Earnings Call Transcript
July 27, 2022 | finance.yahoo.com
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
July 27, 2022 | americanbankingnews.com
Myovant Sciences Ltd. Forecasted to Earn Q1 2023 Earnings of ($0.18) Per Share (NYSE:MYOV)
July 26, 2022 | msn.com
Earnings Outlook For Myovant Sciences
July 26, 2022 | americanbankingnews.com
Myovant Sciences (MYOV) Scheduled to Post Earnings on Wednesday
July 13, 2022 | finance.yahoo.com
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
June 27, 2022 | finance.yahoo.com
Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
June 20, 2022 | finance.yahoo.com
Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?
See More Headlines
Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Company Calendar

Last Earnings
10/26/2021
Today
8/19/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:MYOV
Previous Symbol
NASDAQ:MYOV
CUSIP
N/A
CIK
1679082
Web
www.myovant.com
Phone
442074003351
Fax
N/A
Employees
407
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.67
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+0.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-205,980,000.00
Net Margins
-54.03%
Pretax Margin
-50.02%
Return on Equity
N/A
Return on Assets
-29.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.89
Quick Ratio
1.79

Sales & Book Value

Annual Sales
$230.97 million
Price / Sales
7.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.04) per share
Price / Book
-3.47

Miscellaneous

Outstanding Shares
95,928,000
Free Float
94,105,000
Market Cap
$1.68 billion
Optionable
Not Optionable
Beta
2.40

Key Executives

  • Mr. David C. Marek (Age 57)
    CEO & Director
    Comp: $1.31M
  • Mr. Matthew Lang J.D.Mr. Matthew Lang J.D. (Age 46)
    Gen. Counsel & Corp. Sec.
    Comp: $1.03M
  • Mr. Uneek Mehra
    Chief Financial & Bus. Officer
  • Mr. Albert Liao
    Director of Corp. Communications
  • Mr. Bryan Selby
    Sr. VP of Product Devel.
  • Dr. Juan Camilo Arjona Ferreira M.D. (Age 52)
    Chief Medical Officer
  • Dr. Teresa Perney Ph.D.
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Andria Langenberg M.D. (Age 65)
    Head of Drug Safety & Pharmacovigilance
  • Mr. Jeffrey D. Nornhold (Age 56)
    Sr. VP of Pharmaceutical Operations & Devel.
  • Ms. Lauren Merendino (Age 47)
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MYOV Stock - Frequently Asked Questions

Should I buy or sell Myovant Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MYOV shares.
View MYOV analyst ratings or view top-rated stocks.

What is Myovant Sciences' stock price forecast for 2022?

3 brokerages have issued 1 year price targets for Myovant Sciences' stock. Their MYOV share price forecasts range from $10.00 to $23.00. On average, they predict the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price.
View analysts price targets for MYOV or view top-rated stocks among Wall Street analysts.

How have MYOV shares performed in 2022?

Myovant Sciences' stock was trading at $15.57 at the beginning of the year. Since then, MYOV shares have increased by 12.5% and is now trading at $17.51.
View the best growth stocks for 2022 here.

Are investors shorting Myovant Sciences?

Myovant Sciences saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 3,060,000 shares, a decrease of 18.6% from the June 30th total of 3,760,000 shares. Based on an average daily volume of 758,900 shares, the short-interest ratio is presently 4.0 days. Currently, 7.3% of the company's shares are short sold.
View Myovant Sciences' Short Interest.

When is Myovant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our MYOV earnings forecast.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) released its earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.11. The firm earned $77.90 million during the quarter, compared to analysts' expectations of $72.67 million. During the same quarter in the previous year, the business earned ($0.75) earnings per share.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (2.33%), Goldman Sachs Group Inc. (0.44%), Platinum Investment Management Ltd. (0.31%), Hennion & Walsh Asset Management Inc. (0.29%), Renaissance Technologies LLC (0.29%) and Millennium Management LLC (0.28%). Insiders that own company stock include Chemical Co Ltd Sumitomo, David C Marek, Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, Lauren Merendino, Matthew Lang and Sciences Ltd Roivant.
View institutional ownership trends.

How do I buy shares of Myovant Sciences?

Shares of MYOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $17.51.

How much money does Myovant Sciences make?

Myovant Sciences (NYSE:MYOV) has a market capitalization of $1.68 billion and generates $230.97 million in revenue each year. The company earns $-205,980,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Myovant Sciences have?

The company employs 407 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The official website for the company is www.myovant.com. The company can be reached via phone at 442074003351 or via email at investors@myovant.com.

This page (NYSE:MYOV) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.